Exploration of individual beta cell function over time in vivo: effects of hyperglycemia and glucagon-like peptide-1 receptor (GLP1R) agonism
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 5, 2025
The
coordinated
function
of
beta
cells
within
the
pancreatic
islet
is
required
for
normal
regulation
insulin
secretion
and
partly
controlled
by
specialized
"leader"
highly
connected
"hub"
beta-cell
subpopulations.
Whether
these
subpopulations
are
functionally
stable
in
vivo
remains
unclear.
Here,
we
establish
an
approach
to
monitor
Ca
2+
dynamics
individual
over
time,
after
engraftment
into
anterior
eye
chamber,
where
continuous
blood
perfusion
near
innervation
pertain.
Under
normoglycemic
conditions,
network
dynamics,
behavior
leaders
hubs,
remain
at
least
seven
days.
Hyperglycemia,
resulting
from
high-fat
diet
feeding
or
loss
a
host
Gck
allele,
caused
engrafted
islets
display
incomplete
abortive
waves
overall
connectivity
was
diminished.
Whereas
hub
cell
numbers
were
lowered
profoundly
both
disease
models,
largely
persisted.
Treatment
with
GLP1R
agonist
Exendin-4
led
recovery
islet-wide
re-emergence
minutes,
effects
incretin
mimetic
being
more
marked
than
those
observed
analogous
treatments
vitro
.
Similar
observations
made
using
3-dimensional
imaging
across
whole
islet.
Our
findings
thus
suggest
that
incretins
may
act
directly
indirectly
on
vivo.
described
provide
broad
applicability
exploration
time
living
animal.
Язык: Английский
Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review
Obesities,
Год журнала:
2025,
Номер
5(2), С. 26 - 26
Опубликована: Апрель 18, 2025
Obesity
represents
a
global
health
challenge,
with
critical
and
urgent
need
for
long-term,
sustainable
management
strategies.
Tirzepatide
is
novel
dual
glucose-dependent
insulinotropic
polypeptide
(GIP)
glucagon-like
peptide-1
(GLP-1)
receptor
agonist.
At
first
approved
the
treatment
of
type
2
diabetes
mellitus,
tirzepatide
one
latest
clinically
commercially
available
pharmacological
options
obesity
management.
This
narrative
review
aimed
to
synthesize
existing
clinical
evidence
on
efficacy
safety
in
non-diabetic
obese
individuals.
A
comprehensive
literature
search
was
conducted
using
PubMed,
Scopus,
Web
Science,
ClinicalTrials.gov,
Google
Scholar
databases
identify
relevant
trials,
meta-analyses,
original
studies
assessing
weight-loss
impact
from
2022
onwards.
Synthesized
indicated
that
achieved
up
20.9%
weight
loss
over
72
weeks
(SURMOUNT-1),
18.4%
after
lifestyle
intervention
(SURMOUNT-3),
17.5%
Chinese
adults
(SURMOUNT-CN),
25.3%
continued
88
(SURMOUNT-4).
Meta-analyses
confirmed
higher
odds
≥5–20%
versus
semaglutide
liraglutide,
significantly
reducing
body
mass
index,
waist
circumference,
blood
pressure,
atherosclerotic
cardiovascular
disease
risk.
Health-related
quality
life
improved
greater
loss,
gastrointestinal
side
effects
(nausea,
diarrhea,
constipation)
were
common
but
mild
moderate,
<5%
discontinuation.
significant
cardiometabolic
benefits,
individuals,
further
research
needed
long-term
efficacy,
safety,
application.
Язык: Английский